Lebrikizumab Found Safe, Effective in Patients With Skin of Color With AD: Daily Dose

_{©New Africa/AdobeStock}

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

On June 11, 2025, we reported on the final results from the phase 3b ADmirable clinical trial presented at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, TN.

The study

The ADmirable trial is the first prospective study of a biologic in a cohort composed exclusively of patients with skin of color and moderate-to-severe atopic dermatitis (AD). The open-label, single-arm study (NCT05372419) enrolled 90 biologic-naïve patients aged ≥12 years with Fitzpatrick skin types IV–VI and chronic, moderate-to-severe AD not adequately controlled by topical therapies. Participants received lebrikizumab 250 mg subcutaneously every 2 weeks following a 500 mg loading dose at baseline and week 2. Responders at week 16 transitioned to once-monthly dosing through week 24.

The findings

At week 24, 78% of participants achieved EASI 75 (≥75% improvement from baseline), 47% achieved EASI 90, and 54% reached IGA 0/1 with ≥2-point improvement. Clinically meaningful itch reduction (≥4-point improvement on the pruritus numeric rating scale [NRS]) was reported by 60% of participants. Improvements in Dermatology Life Quality Index (DLQI) scores were also seen in 73% of participants.

In addition to improvements in disease severity and symptoms, lebrikizumab also reduced pigmentary sequelae, a common concern in patients with skin of color. Among patients with baseline hyperpigmentation (n = 52), 64% showed improvement by week 24. Of those with baseline hypopigmentation (n = 16), 25% improved. Few patients transitioned from one pigmentary change to another.

Click here for more details.